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Objective: Saphenous vein grafts suffer from neointima formation following bypass surgery. Matrix metalloproteinases
(MMPs) play important roles in this process. We examined MMP-3 for its therapeutic potential to prevent smooth muscle
cell migration and neointima formation in venous bypass grafts using adenovirus-mediated gene transfer.
Methods: Human aortic smooth muscle cells (HASMC) were transduced with adenoviral vectors encoding ß-galactosidase
(AVEßgal) or human MMP-3 (hMMP-3), and characterized for migration in the amniotic membrane stroma as an in
vitro model of the vascular wall. Cholesterol-fed New Zealand white rabbits underwent jugular vein bypass grafting into
carotid arteries. Before insertion, grafts were incubated ex vivo with either AVEßgal or hMMP-3. Transgene expression
was characterized by immunohistochemistry and in situ zymography. Grafts (n  6) were explanted after 28 days and
intimal hyperplasia was quantified.
Results: Migration of HASMC was significantly reduced when transduced with hMMP-3 compared to controls (P <
.001). Immunocytochemistry of hMMP-3 transduced venous grafts localized this protein to the intima. In situ-
zymography showed increased MMP activity in the intima of hMMP-3 transfected grafts. Stenosis degree (P  .001),
intima/media-ratio (P  .023) and lesion thickness (P  .003) were significantly reduced in grafts transduced with
Ad.MMP-3 in comparison to controls. There was no difference inside control groups.
Conclusion: MMP-3 overexpression inhibits formation of intimal hyperplasia in arterialized vein grafts. Adenovirus
mediated gene transfer of MMP-3 may be of clinical use to prevent vein graft stenosis following bypass surgery. (J Vasc
Surg 2009;49:750-8.)
Clinical Relevance: Although vein grafts are conduits of choice for lower extremity and coronary bypass graft surgery,
patency rates of vein grafts remain unsatisfactory. The underlying mechanism for graft stenosis and occlusion is the
development of intimal hyperplasia, caused by smooth muscle cell migration from the vascular media into the intima. The
inhibition of smooth muscle cell migration by gentherapeutic strategies, clinically applicable to veins after harvesting and
before graft insertion, may lead to bypass grafts with improved patency. Here we examine the effect of overexpression of
MMP-3 both in vitro on smooth muscle cell migration and in vivo on development of intimal hyperplasia, aimed to
develop pre-clinical strategies for prevention of vein graft stenosis.Autologous vein grafts are the conduits of choice for
lower extremity and coronary artery bypass graft surgery.
However, only 50%-80% of vein grafts remain patent at 5 to
15 years.1-5 Intimal hyperplasia is the major cause of vein
graft stenosis. Smooth muscle cell (SMC) proliferation and
migration into the intima and their proliferation are key
mechanisms in this process.6,7 Cell migration requires ex-
tracellular matrix (ECM) degradation by a variety of extra-
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750cellular proteinase, among which the matrix metallopro-
teinases (MMPs) play an important role. MMPs can
collectively degrade virtually all ECM components and
have been implicated in a variety of tissue remodeling
processes, including atherosclerosis and intimal thicken-
ing.8 MMP-3 (stromelysin-1) has the broadest substrate
specificity of all MMPs; it degrades collagen types III, IV,
and V, laminin, fibronectin, elastin, and proteoglycans.
MMP-3 is secreted by a variety of cell types including
SMC.9,10 High levels of MMP-3 have been described in
atherosclerotic plaques11 and in the SMC of atherosclerotic
coronary arteries.10 MMP-3 is therefore considered as a
protease supporting SMC-migration and development of
intimal hyperplasia in vascular remodeling.
Paradoxically, a common mutation of the MMP-3-
promoter resulting in reduced MMP-3 expression is asso-
ciated with development of atherosclerosis12 and resteno-
sis.13 In MMP-3 knock-out mice, atherosclerotic plaques
are more instable than in MMP-3 expressing mice.14 Con-
versely, high levels of MMP-3 are associated with increased
risk of myocardial infarction.15 Therefore, the role of
MMP-3 in vascular remodeling remains unclear.
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high levels of MMP-3 inhibit vein graft stenosis. Here we
report that adenovirus-mediated overexpression ofMMP-3
blocks SMC cell migration in vitro and reduces the forma-
tion of intimal hyperplasia in arterialized vein grafts.
MATERIALS AND METHODS
Cells and culture medium. Human aortic smooth
muscle cells (HASMC) were purchased from Clonetics
(San Diego, Calif) and grown in smooth muscle basal
medium supplemented with 10 ng/mL of human epider-
mal growth factor (hEGF), 2 ng/mL of human fibroblast
growth factor (hFGF), 0.39 g/mL of Dexamethasone,
50 g/mL of Gentamycin, 50 ng/mL of Amphotericin-B,
and 5% fetal bovine serum. The cells were used between
passage 2 and 8 in culture. Human 293 embryonic kidney
cells stably transfected with the E1A and E1B genes (kindly
provided by Dr R. Schneider, NYU Medical Center) were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS).
Generation of recombinant adenoviruses and trans-
duction conditions. Adenoviral vectors encoding either
ß-galactosidase or human MMP-3 (hMMP-3) were gener-
ated as described.16,17 Briefly, full length DNA for human
MMP-3 (or ß-galactosidase) was subcloned into a pCMVAd.
The resulting construct, pCMVAd.MMP-3, contained the
MMP-3 cDNA flanked on its 5= end by the cytomegalovi-
rus (CMV) promoter and on its 3= end by a polyadenylation
sequence and several hundred nucleotides of adenovirus
type 5 (Ad dL 309) genome lacking the E1A region.
Linearized plasmids and the Ad dL 309 viral genome were
cotransfected into 293 cells or, for animal experiments, in
N52.E6 cells.
HASMC were transduced with 2  108 pfu/mL (100
pfu/cell). Transduction efficiency ranged 24%-40% as as-
sessed by ß-galactosidase staining of cells transduced with
Ad.ßgal.
Smooth muscle cell invasion of the amniotic
membrane. Human amniotic membranes were prepared
as described.16
Northern blotting. Northern blotting was performed
as described18 using a DIG-labeled cDNA probe to
MMP-3 kindly provided by Dr Markku Kurkinen (Wayne
State University), or an 18S DIG-labeled rRNA probe
(Boehringer, Mannheim, Germany) as a control.
Western blotting and casein zymography. Western
blotting and casein zymography were performed as de-
scribed.19
Ex vivo transduction of vein explants with adeno-
viral vectors. For animal experiments, N52.E6 cell line
(human amniocytes, a generous gift from G. Schiedner and
S. Kochanek, University of Cologne, Germany) was used
for homologous recombination of adenoviral vectors to
avoid the generation of replication-competent adenoviral
vectors. Before grafting into the carotid arteries, excised
jugular veins were incubated for 30 minutes at 37°C under
sterile conditions with adenoviral vectors encoding hMMP-3
or ß-galactosidase (2  109 pfu/mL of Poloxamer 407).Poloxamer 407, reported to increase virus-mediated trans-
duction efficiency 100-fold,20 was used to reduce adenovi-
rus concentration and minimize viral toxicity. After incu-
bation, the transduced veins were washed twice with
phosphate buffer solution (PBS) to remove residual adeno-
viral vectors.
Vein graft model of intimal hyperplasia. Female
New Zealand white rabbits (Charles River GmbH, Sulzfeld,
Germany) of approximately 4 kgwere fed a1% cholesterol diet
fromday7before operationuntil euthanasia. The rabbitswere
pre-anesthetized with ketamine (25 mg/kg) and midazolam
(0.1 mg/kg) intramuscularly (i.m.). An intravenous (i.v.)-
line was placed, 0.04 mg/kg buprenorphine injected and
propofol-1% was triggered i.v. for intubation. After intuba-
tion, anesthesia was maintained by spontaneous breathing
of 40% oxygen and 2%-volume isoflurane. Deepness of
narcosis and life parameters were monitored continuously.
Standard vein graft dissection techniques were used to
collect the left jugular vein, which was transferred to a labora-
tory designed for work with genetically hazardous material
(level SII). Under sterile conditions, the explanted veins were
flushed with PBS, Poloxamer 407 or transduced with adeno-
viral vectors encoding for ß-galactosidase or hMMP-3. After
injection of 100 i.u/kg heparin, the veins were grafted
end-to-side into the carotid artery with prolene 10-0
(Ethicon, Hamburg, Germany). The animals were extu-
bated and monitored in a recovery room for 6 hours
before being transferred back to the animal housing
facility. Perioperatively the animals received a single dose
of penicillin/streptomycin (0.5 mL tardomycel subcuta-
neously [s.c.], Bayer AG, Leverkusen, Germany), and
three daily s.c. injections of carprofene (25 mg). For
harvesting the grafts, the animals were anesthetized with
ketamine (25 mg/kg) and midazolam (0.1 mg/kg) i.m.,
and sacrificed with an i.v. overdose of pentobarbital (300
mg/kg) before making the skin incision. Harvested
grafts were washed with PBS and either embedded in
OCT and snap-frozen in liquid nitrogen, or fixed for later
paraffin embedding. Triplicate animals were used for ana-
lyzing hMMP-3 overexpression at postoperative day 7, and
6 animals/group for characterizing intimal hyperplasia.
Two animals in our series had occluded grafts due to
technical errors and were excluded from analysis.
The animals were treated in accordance with the Ger-
man animal welfare law and European Union guidelines.
Institutional approval for animal experiments was obtained
(No. 509.6-42502-99/201). The investigation conforms
to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996).
Immunohistochemistry. Ten-micrometer frozen sec-
tions were incubated with mouse anti-MMP3 monoclonal
antibody (No. 1339, Chemicon) diluted 1:100 overnight at
4°C, followedby30minutes of incubationwith FITC-labeled
goat-anti-mouse antibody [No. AP 124 F Chemicon], and
fixation with mowiol (Hoechst, Frankfurt, Germany). These
MMP-3 antibodies do not crossreact with rabbit-MMP-3.
3 cas
JOURNAL OF VASCULAR SURGERY
March 2009752 Kallenbach et alIn situ-zymography. MMP-3 activity was analyzed
by in situ casein zymography. Vessels were snap frozen in
OCT medium after harvesting and cut into 8-m sections.
The sections were put onto microscope slides and incu-
bated at 37°C for 48 hours in Tris 50 mM, CaCl2 10 mM,
Brij 35 0.05% containing agarose 1% and resorufin-labeled
casein (10 mg/mL; Boehringer, Mannheim, Germany).
Casein degradation was observed with a fluorescence mi-
croscope.
Measurement of neointima formation. Neointima
formation was quantified on cross sections of vein grafts
(6/group) stained with elastica van Gieson (EvG) and
Mayer’s hematoxylin and eosin (H&E). For randomiza-
tion, vessels were longitudinally divided into 6 regions, and
from each region the first cross section was picked for
analysis. Intima, media, internal, and external elastic lamina
were identified and traced on digital images of sections cut
at five spaced intervals using Image-Pro Plus (Version
4.1.5, Cybernetics Inc, Silver Spring, Md). The investiga-
tor was blinded since labeling of cross sections did not allow
identification of experimental group. Three parameters
were calculated: stenosis degree (intima-lumen/lumen),
intima/media ratio (intima-lumen/media-lumen) and le-
sion thickness (radius of the media-radius of the intima).
Statistical analysis. Statistical analysis was performed
by one-way analysis of variance (ANOVA) combined with
post-hoc test LSD using SPSS (Version 12.0, Chicago, Ill).
Any P .05 values were considered statistically significant.
RESULTS
HASMC transduced with Ad.MMP-3 overexpress
functional MMP-3. To study the role of MMP-3 in the
generation of intimal hyperplasia, we used adenovirus me-
diated gene transfer to upregulate MMP-3 expression in
aortic smooth muscle cells. By Northern blotting, hMMP-
Fig 1. Characterization of hMMP-3 overexpression in
analysis of total ribonucleic acid (RNA) from non-trans
proteinases (hMMP)-3-transduced human aortic smooth
express the 2.2 Kb MMP-3 mRNA (rec. hMMP-3). T
Expression of an immunoreactive 57 kDa band consi
transduced HASMC or 293 cells. HASMC grown on
(transfected) produced comparable levels of MMP-3.
transduced 293 cells, or by non-transduced, Ad.ßgal- or h
consistent with theMr of pro-MMP-3 was present only in A
amniotic membrane (transfected/a) showed higher MMP-3-transduced HASMC had high levels of MMP-3 mRNA,whereas control, non-transduced, or Ad.ßgal-transduced
cells showed no such transcript (Fig 1, a). Western blotting
with MMP-3 antibody showed expression of a 57-kDa
band consistent with theMr of pro-MMP-3 (Fig 1, b). This
band was undetectable in the CM of control cells, showing
that non-transduced HASMC expressed no MMP-3. A
similar amount of MMP-3 was present in the CM of
HASMC grown on the amniotic membrane (Fig 1, b, SMC
transduced/a). In vitro experiments with different adeno-
viral vector concentrations showed the highest transduc-
tion efficiency of 24.1% and the lowest cytotoxicity with
2  108 pfu/mL (100 pfu/cell). Dose response experi-
ments showed no relevant increase of transduction effi-
ciency when vector concentration was higher. The growth
rate of virus-transduced cells was slightly but not signifi-
cantly higher that of non-transduced cells (data not
shown), and no difference in viability was observed be-
tween transduced and non-transduced HASMC. Consis-
tent with theWestern blotting result, casein zymography of
medium conditioned by hMMP-3-transduced HASMC
showed a lysis band of 57 kDa (Fig 1, c). This caseinolytic
band was converted to 45 kDa following incubation of the
conditioned medium with 1 mmol/L p-aminophenylmercu-
ric acetate (APMA) at 37°C for 2 hours, indicating activation
of pro-hMMP-3 by cleavage of the pro-domain (data not
shown). Thus, transduction of HASMC with hMMP-3 re-
sulted in overexpression of functional hMMP-3.
Overexpression of MMP-3 inhibits HASMC
migration. To evaluate the effect of MMP-3 gene transfer
on SMC invasion of the extracellular matrix, MMP-3 trans-
duced HASMC were seeded onto the stromal aspect of the
amniotic membrane and SMC-migration was measured. In
the presence of 10 ng/mL of PDGF, non-transduced or
Ad.ßgal-transduced HASMC migrated into the collage-
nous stroma to the same extent. Cells were found at varying
SMC transduced with hMMP-3. a, Northern blotting
, ß-galactosidase (Ad.ßgal)- or human matrix metallo-
cle cells (HASMC). Only cells transduced with hMMP-3
8 s rRNA is shown as a control. b, Western blotting.
with the Mr of pro-MMP-3 is present in hMMP-3-
niotic membrane (transfected/a) or in a culture dish
sein zymography. Medium conditioned by hMMP-3-
-3-transduced HASMC was used. A lysis band of 57 kDa
P-3 transduced cells. TransducedHASMCgrown on the
einolytic activity than cells grown on plastic.HA
duced
mus
he 1
stent
the am
c, Ca
MMP
d.MMdepth in the stromal meshwork; some cells in close contact
ean
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In contrast, only occasional Ad.MMP-3-transduced
HASMC were detected in the superficial layers of the
stroma (Fig 2, c). Counting of the cells in 10 random
high-power (400) microscopic fields showed only single
MMP-3-transduced HASMC in the stroma after 3 or 6
days of incubation (Fig 2, d/graph). In contrast, up to
20-fold more non-transduced or Ad.ßgal-transduced
HASMC were counted under the same conditions (P 
.001). These results indicated that high levels of MMP-3
expression inhibit SMC invasion of a collagenous stroma.
Ex vivo transduction of autologous vein grafts with
hMMP-3 inhibits the development of intimal hyperpla-
sia in vivo. To investigate the role of MMP-3 in the
development of intimal hyperplasia we transduced jugular
vein explants ex vivo and grafted them into the carotid artery
as described under Materials and Methods. Analysis of the
venous grafts by immunocytochemistry and in situ zymogra-
phy 7 days after implantation showed that adenovirus-mediated
gene transfer of hMMP-3 resulted in sustained overexpres-
sion of active hMMP-3. By immunocytochemistry MMP-
3-transduced grafts showed prominent staining in the in-
tima and faint staining in the media (Fig 3, a). Virtually, the
Fig 2. Migration of human aortic smoothmuscle cells (H
extracellular matrix, stimulated with 10 ng/mL of PDGF. a
and were found in various depths of the matrix (arrows).
ß-galactosidase (AVEßgal) before seeding. Cells migrated i
When transduced with hMMP-3 before seeding, HASMC
Number of migrated HASMC was counted by 10 random
Difference between MMP-3-overexpressing HASMC and
controls. Differences in thickness of the membrane (c) rela
eosin (H&E), magnification 400 for all photographs. Mwhole luminal lining of the vessel was stained, indicatinghigh transduction efficiency. Conversely, non-transduced
control grafts showed no specific staining. Similarly, in situ
casein zymography showed high proteolytic activity local-
ized to the intima of MMP-3-transduced grafts (Fig 4, a)
and no caseinolytic activity in control grafts incubated with
PBS alone or transduced with AVEßgal (Fig 4, b, c). Thus,
ex vivo transduction of vein explants resulted in high and
sustained levels of expression of active MMP-3.
To analyze the development of intimal hyperplasia,
vein grafts were harvested 28 days after implantation,
and cross sections were characterized histologically. Sig-
nificant intimal hyperplasia was detected in control vein
grafts incubated with PBS or Poloxamer 407 (Fig 5, a, b;
Fig 6). Similarly, control vein grafts transduced with
ß-gal showed development of intimal hyperplasia com-
parable to the other controls (Fig 5, c). Conversely,
intimal hyperplasia was significantly reduced in vein
grafts transduced with MMP-3 (Fig 5, d), as assessed by
measurement of stenosis degree (P  .001), intima/
media-ratio (P  .023) and lesion thickness (P  .003)
(Fig 6). Therefore, these results showed that overexpres-
sion of MMP-3 inhibits the development of intimal
) through the amnioticmembranemimicking the vascular
reatedHASMCmigrated from the surface into the stroma
SMC were transduced with adenoviral vectors encoding
parable numbers into the stroma as untreated HASMC. c,
invade the stroma and remain on the surface (arrows). d,
roscopic high power fields (HPF) per histologic sections.
ols was highly significant (** P  .001), but not between
atural variability of amnion membrane. Hematoxylin and
standard deviation is shown (d).ASMC
,Unt
b, HA
n com
rarely
mic
contr
te to nhyperplasia in arterialized vein grafts.
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The data presented show that adenovirus-mediated
Fig 3. Immunocytochemical analysis of matrix metalloproteinase
(MMP)-3 in cross-sections of vein grafts 7 days after implantation.
a, Vein graft transduced with human matrix metalloproteinase
(hMMP)-3. b, Non- transduced control. c, Vein graft transduced
with hMMP-3 stained with secondary antibody alone.overexpression of stromelysin-1 (MMP-3) reduces migra-tion of HASMC in an in vitro model of the vascular wall,
and causes reduced development of intimal hyperplasia in
vivo. These findings contrast with the understanding of the
Fig 4. In situ casein zymography of vein grafts 7 days after
implantation. a, Vein graft transduced with human matrix metal-
loproteinase (hMMP)-3. Dark areas in the intima (arrows) indicate
digestion of red-labeled casein. b, Non-transduced control. c,
Adenoviral vectors encoding ß-galactosidase (AVEßgal) transduced
control. No caseinolytic activity is visible in the two controls.role of MMP-3 in the development of intimal hyperplasia.
alm
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ity against components of the extracellular matrix led to the
assumption that – like other proteinases – MMP-3 pro-
motes SMC migration and development of intimal hyper-
plasia. High levels of MMP-3 have been described in ath-
erosclerotic plaques and in the SMC of atherosclerotic
coronary arteries.10,11 Mechanical injury of rabbit vascular
smooth muscle cells (VSMCs) was associated with induc-
tion of stromelysin-1 mRNA expression, migration and
proliferation, and neointima formation after vessel wall
injury of rat carotid arteries was substantially inhibited by
antisense oligonucleotides to stromelysin-1 mRNA.21,22
All these findings supported the hypothesis that MMP-3
promotes SMC migration and development of intimal hy-
Fig 5. Development of intimal hyperplasia in vein graf
Gieson, magnification 20. a, Graft incubated with PB
Comparable amounts of intimal hyperplasia were found i
ex vivo with adenoviral vectors encoding ß-galactosidas
with human matrix metalloproteinase (hMMP)-3 showedperplasia.However, other studies have shown that reduced ex-
pression of MMP-3 in patients with a common 6A/6A
polymorphism leads to increased progression of coronary
atherosclerosis,12 whereas the 5A/6A polymorphism with
higher MMP-3 levels is associated with reduced restenosis
after percutaneous transluminal coronary angioplasty
(PTCA) and stenting compared to patients with 6A/6A
alleles.13 It has been speculated that MMP-3 has a domi-
nant protective effect from lumen loss associated with the
5A allele and consecutive higher MMP-3 levels. Consistent
with this hypothesis, healthy male subjects homozygous for
the 6A allele (ie, with low MMP-3 expression) show in-
creased wall thickness, enlarged arterial lumen, and local
reduction of wall shear stress, whichmight predispose them
after interposition into the carotid artery. Elastica van
ore implantation, showing severe neointima formation.
grafts incubated with Poloxamer 407 (b) or transduced
Eßgal) (c) before implantation. Vein grafts transduced
ost no intimal hyperplasia 28 days after implantation (d).ts 28
S bef
n vein
e (AVto atherosclerotic plaque formation.23 Studies with
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the hypothesis of a protective function of MMP-3 in vas-
cular remodeling. Atherosclerotic plaques in these animals
are four times as large as in apoE/: MMP-3/
mice.14,24 These findings support the hypothesis that high
levels of MMP-3 have a protective role in vascular remod-
eling.
In our study, both migration of HASMC and develop-
ment of intimal hyperplasia were reduced by overexpression
of MMP-3. Initially, we observed reduced migration of
HASMC overexpressing MMP-3 in a Boyden chamber
assay (data not shown). Therefore, to study SMCmigration
in a more physiological setting we used a cell migration
model based on the amniotic membrane.16 The composi-
tion and structure of the amnion extracellular matrix is
more similar to that of vessels than is Matrigel (BD Bio-
sciences, San Jose, Calif). The amniotic membrane has a
dense basement membrane and abundant collagenous
stroma with elastin fibers, which confer great resistance to
traction and resilience on the tissue, making it more similar
to a vessel than Matrigel. Because of the harsh treatment
used to remove the epithelial layer (incubation in 0.25 M
NH4Cl for 1 hour), the occasional fibroblasts present in
the amnion stroma are destroyed, leaving an acellular col-
lagenous matrix. Therefore, in this model the cells that are
found in the stroma are the viable cells that invaded from
the stromal surface. We found that stimulation with PDGF
induced SMC migration and invasion into the amnion
stroma, a process blocked by MMP-3 overexpression. For
practical reasons, we used arterial instead of venous SMC
for our studies. Venous SMC tend to exhibit increased
proliferation andmigration compared to arterial SMC.25-27
However, although we used less motile HASMC, migra-
tion was upregulated by PDGF both in untreated and
Ad.ßgal-transduced cells but not in MMP-3-transduced
Fig 6. Degree of intimal hyperplasia in vein grafts 2
investigated. Lesion thickening, intima/media ratio and
Methods. Mean  standard deviation is shown.cells.The vein graft model of intimal hyperplasia that we
used showed significant reduction of intimal hyperplasia in
grafts transduced with hMMP-3 relative to non-transduced
or Ad.ßGal-transduced controls. Immunocytochemical
and in situ zymography analysis showed that MMP-3 over-
expression in transduced grafts lasted at least 7 days. We did
not characterize MMP-3 expression at 28 days after graft-
ing, the time when intimal hyperplasia was analyzed. Since
adenoviral expression is transient, overexpression is unlikely
to last longer than 4 weeks after transduction. However,
the early development of IH occurs in the first 2 weeks after
venous graft arterialization;28,29 whereas the late remodel-
ing of the arterialized venous graft is essential for adapta-
tion of the vessel wall to the high pressure system. Experi-
ence with drug eluting stents in percutaneous catheter
interventions (PCI) for coronary artery disease shows that
the benefit of early inhibition of intimal hyperplasia lasts
longer than the drug eluting effect for prevention of stent
stenosis. However, from our experiments we have no infor-
mation if longer overexpression of MMP-3 is required for
long-term reduction of intimal hyperplasia in arterilized
vein grafts.
Gene transfer with adenoviral vectors is a potentially
useful technique for this clinical application. For the treat-
ment of vein grafts, the adenoviral vectors are used only ex
vivo, and grafts are flushed several times after transduction
for removal of free adenoviral vectors. Therefore, only trace
amounts of viral vectors are expected to remain in the vein
graft. As long as large numbers of infectious adenoviral
vectors are not injected systemically, the risk for the patient
is extremely low. There are no reports that topical ex vivo
administration of adenoviral vectors results in systemic
complications. Furthermore, to improve the safety for pos-
sible clinical application, we used a relatively low number of
viral infectious units and a cell-system for vector production
after implantation. N  6 animals per group were
sis degree were measured as detailed under Materials and8 day
stenothat makes the development of replication-competent ad-
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perfect delivery vehicle for gene transfer still remains un-
available.
The mechanism by which MMP-3 reduces SMC-
migration and intimal hyperplasia remains unclear. The
observation that relatively low transduction efficiency re-
sulted in almost complete reduction of migration in vitro,
presumably including uninfected cells, suggest that the
underlying effect is not cell-specific. It is possible that
MMP-3 degrades PDGF, thus depriving vascular smooth
muscle cells of the major inducer of cell migration. How-
ever, this hypothesis has not been tested. Based on existing
reports, we speculate that excess stromal degradation by
high levels of MMP-3 deprive SMC of anchorage sites
required for migration. This hypothesis is consistent with
previous findings that inhibition of cell attachment to Ma-
trigel inhibits cell migration.30 Fibronectin (FN) mediates
cell adhesion, migration, and cytodifferentiation,31 and
SMC uses FN to bind to type I and III collagens.32 Intact
FN (and laminin) is therefore essential for SMC migration.
Because FN and laminin are substrates for MMP-3, it is
possible that excess degradation of these (and other) extra-
cellular matrix proteins byMMP-3 results in impaired SMC
migration. The theory of “no grip, no invasion” has been
discussed elsewhere33 and is supported by findings that
excessive proteolysis can cause damage to the tissue and
dissolve the matrix needed for anchoring the migrating
cells.34,35 This view is also supported by a recent study
showing that MMP-3 knockdown skeletal muscle satellite
cells migrated faster than controls.36
MMP-3 can promote extracellular matrix degradation
directly and indirectly by activating other MMPs, including
MMP-9 and MMP-7.8,18 The collective action of these
MMPs in the graft may, therefore, cause excessive degra-
dation of the extracellular matrix, generating microenvi-
ronmental conditions that are not permissive for SMC
migration.
In addition, MMP-3 may play a role in the chemo-
tactic recruitment of a number of inflammatory cell types
directly37,38 or through the chemotactic action of protein
(eg, laminin) degradation products.39 Additional secretion
of MMPs (eg, MMP-9) from attracted macrophages will
result in increased proteolytic activity.
Thus, a variety of observations support the concept that
MMP-3 has beneficial effects on venous vascular remodel-
ing in the setting of venous grafting. Further studies are
warranted to clarify the role of MMP-3 in plaque rupture,
restenosis, and narrowing of arterialized autologous vein
grafts, and to investigate the therapeutic potential of
MMP-3 overexpression in the vascular wall.
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